Association of Infliximab and Vedolizumab Trough Levels with Reported Rates of Adverse Events: A Cross-Sectional Study.

Veisman, Ido; Barzilay, Oranit; Bruckmayer, Liora; Haj-Natour, Ola; Kopylov, Uri; Eliakim, Rami; Ben-Horin, Shomron; Ungar, Bella

Veisman, Ido; Barzilay, Oranit; Bruckmayer, Liora; Haj-Natour, Ola; Kopylov, Uri; Eliakim, Rami; Ben-Horin, Shomron; Ungar, Bella.

Afiliação

Veisman I; Sheba Medical Center Tel Hashomer, Department of Gastroenterology, Ramat Gan 52620, Israel.
Barzilay O; Sackler School of Medicine, Tel-Aviv University, Tel Aviv-Yafo 67011, Israel.
Bruckmayer L; Sheba Medical Center Tel Hashomer, Department of Gastroenterology, Ramat Gan 52620, Israel.
Haj-Natour O; Sackler School of Medicine, Tel-Aviv University, Tel Aviv-Yafo 67011, Israel.
Kopylov U; Sheba Medical Center Tel Hashomer, Department of Gastroenterology, Ramat Gan 52620, Israel.
Eliakim R; Sackler School of Medicine, Tel-Aviv University, Tel Aviv-Yafo 67011, Israel.
Ben-Horin S; Sheba Medical Center Tel Hashomer, Department of Gastroenterology, Ramat Gan 52620, Israel.
Ungar B; Sackler School of Medicine, Tel-Aviv University, Tel Aviv-Yafo 67011, Israel.

J Clin Med ; 10(18)2021 Sep 20.

Article em En | MEDLINE | ID: mdl-34575376

Palavras-chave

IBD; biological therapy; infliximab; vedolizumab

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Observational_studies / Prevalence_studies / Risk_factors_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google